Why the study?
Vascular endothelial growth factor-B (VEGF-B) binds to VEGF receptor-1 and neuropilin-1 and is abundantly expressed in the heart, skeletal muscle, and brown fat, but its biological function was incompletely understood.
Does VEGF-B overexpression induce angiogenesis, vascular leak, inflammation, or coronary vessel growth in mice and rats?
Does VEGF-B overexpression induce angiogenesis, vascular leak, inflammation, or coronary vessel growth in mice and rats?
VEGF-B acts as a coronary growth factor in rats, increasing arterial supply to the subendocardial myocardium without inducing vascular leak or inflammation, suggesting therapeutic potential for ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Supports selective coronary growth by VEGF-B in rats without leak or inflammation; leaves open therapeutic translation to human ischemic disease.
BACKGROUND: Vascular endothelial growth factor-B (VEGF-B) binds to VEGF receptor-1 and neuropilin-1 and is abundantly expressed in the heart, skeletal muscle, and brown fat. The biological function of VEGF-B is incompletely understood. METHODS AND RESULTS: Unlike placenta growth factor, which binds to the same receptors, adeno-associated viral delivery of VEGF-B to mouse skeletal or heart muscle induced very little angiogenesis, vascular permeability, or inflammation. As previously reported for the VEGF-B(167) isoform, transgenic mice and rats expressing both isoforms of VEGF-B in the myocardium developed cardiac hypertrophy yet maintained systolic function. Deletion of the VEGF receptor-1 tyrosine kinase domain or the arterial endothelial Bmx tyrosine kinase inhibited hypertrophy, whereas loss of VEGF-B interaction with neuropilin-1 had no effect. Surprisingly, in rats, the heart-specific VEGF-B transgene induced impressive growth of the epicardial coronary vessels and their branches, with large arteries also seen deep inside the subendocardial myocardium. However, VEGF-B, unlike other VEGF family members, did not induce significant capillary angiogenesis, increased permeability, or inflammatory cell recruitment. CONCLUSIONS: VEGF-B appears to be a coronary growth factor in rats but not in mice. The signals for the VEGF-B-induced cardiac hypertrophy are mediated at least in part via the endothelium. Because cardiomyocyte damage in myocardial ischemia begins in the subendocardial myocardium, the VEGF-B-induced increased arterial supply to this area could have therapeutic potential in ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Bry et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: